Combined with the fact that MEK1 is essential for regulation of cell growth and downregulates MGMT36, our network results suggest that single agent MEK1 inhibitor therapy or concurrent MEK1 inhibition and chemotherapy may be good strategies to be tested in GBM tumor lines. Here, MAP2K1 is linked to glioblastoma.